

In the Specification:

Please amend the paragraph at page 12, lines 14-26, as follows:

The immunogenic fragments of the polypeptide vaccines disclosed according to the invention will include immunogenic fragments of Sp128 (SEQ ID NO:6), which fragments can be readily screened for immunogenic activity, as well as immunogenic fragments of Sp130 (SEQ ID NO: 8). For example, in the amino acid sequence of Sp130, the fragment corresponding to residues 657 through 773 are known to provide about 40% protection versus the entire Sp130 sequence. Thus, the former fragment protects about 4 out of 10 mice challenged with *Streptococcus pneumoniae* versus 10 of 10 for the entire Sp130 sequence. Thus, specific ~~fragment~~ fragments may include the fragments having amino acid sequences 650 – 773, 640 – 773, 630 – 773, 620 – 773, 610 – 773, 600 – 773, and similar fragments up to the entire Sp130 sequence (SEQ ID NO: 8). It is logical to presume that fragments of Sp128 (SEQ ID NO: 6) may provide similar ~~degress~~ degrees of protection versus the entire Sp128 protein.